A recent study also found that not a single transgender or gender-diverse child younger than 12, in a group of about 5 million youth studied, received hormones.
“It echoes past work that has found that gender-affirming medical care, including puberty blockers and hormone treatment, is ...
The study, which analyzed insurance claims covering more than 5 million patients, provides clearer context as lawmakers ...
HealthDay on MSN22h
Gender-Affirming Medication Use Rare in U.S. Transgender Adolescents From 2018 to 2022Among privately insured U.S. adolescents who identified as transgender and gender-diverse (TGD), receipt of puberty blockers ...
The use of gender-affirming medical care for trans teens was rare between 2018 to 2022, according to a new study published in ...
Gender-affirming care was rarely provided to minors from 2018 through 2022, according to new research out of Harvard ...
The findings, published in JAMA Pediatrics, suggest that fewer than 0.1% of all youth in the database received these medications. Only 926 adolescents were prescribed puberty blockers, and 1,927 ...
Over the past 15 years, new prescribing of puberty blockers for New Zealand children has increased sevenfold, to a level much ...
On 21 November the Ministry of Health released its long awaited position statement, accompanied by an evidence brief, on the safety and long-term impacts of puberty blockers (a non-medical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback